ELEV Elevation Oncology, Inc.

Elevation Oncology Inc is an oncology company focused on the development of targeted therapeutics for the treatment of cancer in genomically defined patient populations. Its lead program is focused on neuregulin-1, or NRG1, fusions, which are rare genomic alterations that have the potential to be therapeutically actionable through targeted HER3 inhibition.

$6.08
As of 12/03/2021     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  10/22/2012
Outstanding shares:  23,225,637
Average volume:  12,278
Market cap:   $148,411,820
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    28623U101
ISIN:        US28623U1016
Sedol:      
Valuation   (See tab for details)
PE ratio:   0.00
PB ratio:   0.94
PS ratio:   0.00
Return on equity:   -20.92%
Net income %:   0.00%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy